Role of adjuvant chemoradiotherapy for abdominal malignancies.
The rationale for combining surgery, radiotherapy and chemotherapy is discussed and the clinical results seen with surgery and adjuvant radiochemotherapy in three major abdominal malignancies are reviewed. A systematic approach to the literature was used. In rectal cancer, postoperative radiochemotherapy is an established treatment, although there is weak scientific support for the combined approach. The same clinical gains can also be reached much more easily with preoperative radiotherapy. In gastric cancer, a recent large randomised trial showed improved survival from postoperative radiotherapy. This was not seen in a comparably large trial in pancreatic cancer. The reasons for the different results according to primary tumour site are discussed. It is argued that adequate coverage of all adjacent regional lymph node stations is necessary for an effect on survival.
Glimelius
Bengt
B
Department of Oncology, Radiology and Clinical Immunology, Uppsala, Sweden. bngt.glimelius@onkologi.uu.se
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000592:standards; D006801:Humans; D010190:Pancreatic Neoplasms / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000601:surgery / Q000628:therapy*; D013274:Stomach Neoplasms / Q000601:surgery / Q000628:therapy*
D000276:Adjuvants, Immunologic